MannKind is trading at $3.99 (5% up) in pre-market, rebounding from recent weakness as traders position ahead of the August 5, 2026, Q2 earnings report.
- Analysts expect revenue of approximately $108.8 million and a small loss, with a primary focus on the commercial execution of Furoscix ReadyFlow.
- Broader strength in Nasdaq futures is providing an additional supportive backdrop for the move.